Assistant Professor @USFHealth, Cardiovascular Scientist, #Cardiometabolic Disease, #HeartFailure @ECI_ISHR https://xitter.cf/t.co/0hfSNN8buc
Joined July 2023
- Tweets146
- Following187
- Followers101
- Likes191
Sharp Laboratory retweeted
Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction academic.oup.com/eurheartj/a…
Check out the latest research from @LeferLab
Sharp Laboratory retweeted
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
Sharp Laboratory retweeted
Still in Milan 🇮🇹 and bringing the science! 🧪🔥Today, Dr. Cristina Rondinone presented our latest results at #EASD2026:🧬A novel unimolecular tetra-agonist targeting GLP-1, GIP, amylin & calcitonin receptors shows superior weight loss vs. tirzepatide or CagriSema in obese rats🐀
Sharp Laboratory retweeted
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.
Sharp Laboratory retweeted
The suppressed report that concluded there is no protective or safe level of alcohol consumption, now published. It was commissioned by US Congress
Report jsad.com/doi/10.15288/jsad.2…
Editorial jsad.com/doi/epdf/10.15288/j…
"Despite the study’s adherence to its mandate, its findings were sidelined.”
Sharp Laboratory retweeted
In today's @TheLancet there are 3 papers on cardiometabolic disease: biology, epidemiology, prevention/treatment.
The sobering and all to common story from womb to tomb conveyed in this graphic
thelancet.com/journals/lance…
thelancet.com/journals/lance…
thelancet.com/journals/lance…
Sharp Laboratory retweeted
I'm going through the retatrutide phase 3 data, and the cardiometabolic numbers are more interesting than the weight loss:
- 24.1 cm off the waist on 12mg (9.5 inches)
- significant drops in systolic blood pressure
- triglycerides down
- non-HDL cholesterol down
- hsCRP down (a key marker of inflammation)
I'm giving it a few years before people realize GLP-1s are more than just weight loss drugs.
This Post is from a suspended account. Learn more
Sharp Laboratory retweeted
Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss.
gift link nytimes.com/2026/05/21/scien…
Sharp Laboratory retweeted
Impressive TRIUMPH-1 #weightloss data for retatrutide investor.lilly.com/news-rele…
Sharp Laboratory retweeted
In SURPASS CVOT tirzepatide was associated with a reduced risk of major kidney events driven by a reduction in new-onset macroalbuminuria in PPL with low-to-moderate-risk CKD #T2D and slowed decline in kidney function in high-risk chronic kidney disease. thelancet.com/journals/landi…
Sharp Laboratory retweeted
In people with HFpEF (heart failure with preserved ejection fraction) and severe obesity, there is a heart muscle cell defect with sarcomere hyper-phosphorylation. Besides weight loss, sarcomere enhancers (not yet studied) may help.
@ScienceMagazine
science.org/doi/10.1126/scie…
Sharp Laboratory retweeted
The rapidly evolving landscape of incretin-based therapies, including GLP1 agonists, necessitates rethinking trial design. Authors present challenges of placebo-controlled trials & potential ways to limit placebo exposure ahajrnls.org/4t0TrPa
Sharp Laboratory retweeted
Multi-organ physiologic deficits during exercise and their metabolic signatures predict incident HFpEF and HF outcomes ahajrnls.org/41k5Hy2
Sharp Laboratory retweeted
Everyone's talking about retatrutide for weight loss (28.7%). Almost nobody's talking about what it does to your liver.
More than 80% reduction in liver fat. Over 90% normalization rates. In a body composition substudy from the Phase 3 program.
100 million Americans have fatty liver disease. Most don't know it. There's no FDA-approved treatment for it besides "lose weight and hope."
Retatrutide's glucagon receptor activation appears to directly target hepatic fat metabolism not just as a side effect of weight loss, but as a primary mechanism.
This isn't a weight loss drug that happens to help your liver. It might be a liver drug that happens to cause weight loss.
Phase 3 weight loss data drops first half of 2026.
Watch this space.
Sharp Laboratory retweeted
Proposed Multidisciplinary Transition Protocol For Patients Undergoing Treatment Using GLP-1RA
dom-pubs.onlinelibrary.wiley…
@DrNadolsky @NutritionMadeS3 @drmatthewnagra @BevTchangMD @MichaelAlbertMD
Sharp Laboratory retweeted
A new review of the GLP-1 receptor drugs @NEJM
nejm.org/doi/full/10.1056/NE…
surprisingly, the word inflammation only appears once, in this diagram
Sharp Laboratory retweeted
Important new #weightloss option for people with overweight and #obesity Orforglipron, the first
@US_FDA approved small molecule GLP-1 medicine. Innovation from Chugai and Eli Lilly investor.lilly.com/news-rele…
Sharp Laboratory retweeted
Hyperinsulinemia, adiposity, causality and #obesity The latest perspectives nature.com/articles/s41574-0…
Sharp Laboratory retweeted
👉 Metabolic Disorders and Cardiovascular Disease: Key Insights
👆 A recent ESC scientific statement highlights the central role of metabolic dysfunction in cardiovascular disease and the therapeutic implications of emerging cardiometabolic therapies.
👆 Key points:
📍 Cardiovascular disease is increasingly driven by metabolic dysfunction—obesity, type 2 diabetes, and dyslipidaemia act synergistically to accelerate atherosclerosis, heart failure, and arrhythmias.
📍 Metabolic disease disrupts myocardial energetics, promoting metabolic inflexibility, mitochondrial dysfunction, oxidative stress, and lipotoxicity.
📍 Modern cardiometabolic drugs provide benefits beyond glucose lowering.
SGLT2 inhibitors and GLP-1–based therapies improve cardiovascular outcomes through pleiotropic mechanisms.
📍 Atherogenic risk extends beyond LDL-C, with triglyceride-rich lipoproteins and Lp(a) contributing to residual cardiovascular risk.
📍 Future progress will require a systems-biology approach, integrating multi-organ mechanisms, multi-omics data, and translational research.
👆 Bottom line:
Cardiovascular disease should increasingly be understood as a systemic cardiometabolic disorder rather than an isolated vascular pathology.
🔗 Open Access academic.oup.com/eurheartj/a…
@society_eas
@escardio
